帕博利珠单抗治疗的黑色素瘤患者甲状腺相关不良事件的发生率
在一项扩展准入计划中前瞻性监测99例接受帕博利珠单抗治疗的晚期黑色素瘤患者的甲状腺功能,17例发生18起甲状腺功能障碍不良事件,其中甲状腺毒症12例(9例进展为甲状腺功能减退),孤立性甲状腺功能减退6例,15例甲状腺功能减退患者中10例需左甲状腺素治疗。结论认为甲状腺功能障碍常见,推荐抗PD-1单克隆抗体治疗期间系列监测甲状腺功能。
要点
- 99例接受帕博利珠单抗治疗的晚期黑色素瘤患者中,17例发生18起甲状腺功能障碍不良事件。
- 甲状腺毒症12例,其中9例进展为甲状腺功能减退;孤立性甲状腺功能减退6例;15例甲状腺功能减退患者中10例需左甲状腺素治疗。
- 所有7例进展为甲状腺功能减退的甲状腺毒症患者均见甲状腺弥漫性18FDG摄取增高。
核心结论
- 甲状腺功能障碍在接受帕博利珠单抗治疗的黑色素瘤患者中常见,甲状腺功能减退和与炎性甲状腺炎相关的甲状腺毒症是最常见表现。
- 作者认为抗PD-1单克隆抗体治疗期间应系列监测甲状腺功能。
- 与炎性甲状腺炎相符的甲状腺毒症与甲状腺弥漫性18FDG摄取增高相关。
- 作者认为甲状腺自身抗体的前瞻性作用及组织病理学相关性需进一步研究。
研究设计与样本
- 在转诊肿瘤中心的扩展准入计划中,前瞻性监测开始帕博利珠单抗治疗的黑色素瘤患者的甲状腺功能。
- 纳入99例接受至少一次帕博利珠单抗给药的晚期黑色素瘤患者,年龄26.3-93.6岁,女性占63.6%。
- 对符合炎性甲状腺炎的病例回顾18氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(18FDG-PET/CT)的摄取情况。
主要发现
- 17例患者共观察到18起甲状腺功能障碍不良事件。
- 甲状腺毒症发生于12例患者,其中9例进展为甲状腺功能减退。
- 孤立性甲状腺功能减退见于6例患者。
- 15例甲状腺功能减退患者中10例需要左甲状腺素治疗。
- 10例甲状腺功能障碍患者中4例甲状腺自身抗体升高;所有7例进展为甲状腺功能减退的甲状腺毒症患者均见甲状腺弥漫性18FDG摄取增高。
临床怎么用
- 作者认为抗PD-1单克隆抗体治疗期间应系列监测甲状腺功能。
- 作者认为甲状腺自身抗体的前瞻性作用及组织病理学相关性需进一步研究。
局限性
- 作者认为甲状腺自身抗体的前瞻性作用及组织病理学相关性需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Immune checkpoint blockade is associated with endocrine-related adverse events. Thyroid dysfunction during pembrolizumab therapy, an anti-programmed cell death 1 (PD-1) receptor monoclonal antibody, remains to be fully characterized. OBJECTIVE: To assess the incidence and characteristics of pembrolizumab-associated thyroid dysfunction. DESIGN AND SETTING: Thyroid function was monitored prospectively in melanoma patients who initiated pembrolizumab within an expanded access program at a referral oncology center. 18Fluorodeoxyglucose uptake on positron emission tomography/computed tomography (18FDG-PET/CT) was reviewed in cases compatible with inflammatory thyroiditis. PATIENTS: Ninety-nine patients with advanced melanoma (age, 26.3-93.6 years; 63.6% females) who received at least one administration of pembrolizumab. MAIN OUTCOME MEASURES: Patient characteristics, thyroid function (TSH, free T4), thyroid autoantibodies, and 18FDG-PET/CT. RESULTS: Eighteen adverse events of thyroid dysfunction were observed in 17 patients. Thyrotoxicosis occurred in 12 patients, of which nine evolved to hypothyroidism. Isolated hypothyroidism was present in six patients. Levothyroxine therapy was required in 10 of 15 hypothyroid patients. Thyroid autoantibodies were elevated during thyroid dysfunction in four of 10 cases. Diffuse increased 18FDG uptake by the thyroid gland was observed in all seven thyrotoxic patients who progressed to hypothyroidism. CONCLUSIONS: Thyroid dysfunction is common in melanoma patients treated with pembrolizumab. Hypothyroidism and thyrotoxicosis related to inflammatory thyroiditis are the most frequent presentations. Serial measurements of thyroid function tests are indicated during anti-PD-1 monoclonal antibody therapy. Thyrotoxicosis compatible with inflammatory thyroiditis was associated with diffuse increased 18FDG uptake by the thyroid gland. The prospective role of thyroid autoantibodies should be further investigated, together with the histopathological correlates.
引用
- de Filette J, Jansen Y, Schreuer M, et al. Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab. J Clin Endocrinol Metab. 2016. PMID: 27571185
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。